 | |
| Clinical data | |
|---|---|
| Other names | AXS17; BAER101; AZD7325; AZ-7325; AZ7325 |
| Drug class | GABAA receptor positive allosteric modulator;Nonbenzodiazepine |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C19H19FN4O2 |
| Molar mass | 354.385 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
AXS-17, also known asBAER-101 or asAZD-7325, is aGABAA receptor positive allosteric modulator andnonbenzodiazepine which is under development for the treatment ofanxiety disorders andabsence epilepsy.[1][2][3] It is or was also under development forautism spectrum disorder,fragile X syndrome, and otherneurological disorders, but no recent development has been reported for these indications.[2] The drug is a GABAA receptorα2 andα3 subunit-selectivepartial positive allosteric modulator acting via thebenzodiazepine site.[2][1][3] It might have reducedside effects compared to non-selective high-efficacy positive allosteric modulators like thebenzodiazepinesdiazepam andlorazepam.[4] In terms ofchemical structure, AXS-17 is acinnolinederivative.[1] AXS-17 was originated byAstraZeneca and theUniversity College London.[2] It was licensed and under development by Avenue Therapeutics's Baergic Bio, but was later acquired by Axsome Therapeutics, which is now developing the drug.[2][5] As of November 2025, AXS-17 is inphase 2clinical trials for anxiety disorders and is in thepreclinical research stage of development for absence epilepsy.[2] AXS-17 was first described in thescientific literature by at least 2012.[6][4]
 | This article about ananxiolytic is astub. You can help Wikipedia byadding missing information. |
 | Thisanticonvulsant-related article is astub. You can help Wikipedia byadding missing information. |